论文信息 - Cefepime/sulbactam as an enhanced antimicrobial combination therapy for the treatment of MDR Gram-negative infections-authors' response. - 字舞流文

Cefepime/sulbactam as an enhanced antimicrobial combination therapy for the treatment of MDR Gram-negative infections-authors' response.

D. Wareham | J. Standing | M. Hornsey | L. Phee | M. H. F. Abdul Momin

[1] K. Bowker,et al. Comment on: Cefepime/sulbactam as an enhanced antimicrobial combination therapy for the treatment of MDR Gram-negative infections. , 2020, Journal of Antimicrobial Chemotherapy.

[2] D. Wareham,et al. Cefepime/sulbactam as an enhanced antimicrobial combination therapy for the treatment of MDR Gram-negative infections. , 2019, The Journal of antimicrobial chemotherapy.

[3] Ronald N. Jones,et al. Antimicrobial Activity of High-Proportion Cefepime-Tazobactam (WCK 4282) against a Large Number of Gram-Negative Isolates Collected Worldwide in 2014 , 2017, Antimicrobial Agents and Chemotherapy.

[4] Brian T. Tsuji,et al. High-Dose Ampicillin-Sulbactam Combinations Combat Polymyxin-Resistant Acinetobacter baumannii in a Hollow-Fiber Infection Model , 2017, Antimicrobial Agents and Chemotherapy.

[5] D. Ehmann,et al. Molecular Mechanisms of Sulbactam Antibacterial Activity and Resistance Determinants in Acinetobacter baumannii , 2015, Antimicrobial Agents and Chemotherapy.

[6] E. Douzinas,et al. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. , 2008, The Journal of infection.